These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29629673)

  • 21. Antibiotic susceptibility of Serratia marcescens and Serratia liquefaciens.
    Traub WH
    Chemotherapy; 2000; 46(5):315-21. PubMed ID: 10965096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nosocomial strain of Serratia marcescens producing a new type of extended spectrum beta-lactamase transfers multidrug resistance.
    Babalova M; Blahova J; Kralikova K; Krcmery V; Jezek P; Rovny I
    J Chemother; 2006 Jun; 18(3):334-5. PubMed ID: 17129849
    [No Abstract]   [Full Text] [Related]  

  • 23. [Corneal ulcer caused by Serratia marcescens: case report].
    Aprelev AE; Iakovleva NA; Valyshev AV
    Vestn Oftalmol; 2013; 129(1):53-5. PubMed ID: 23650750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of an SME-2-producing Serratia marcescens isolate in Canada.
    Carrër A; Poirel L; Pitout JD; Church D; Nordmann P
    Int J Antimicrob Agents; 2008 Feb; 31(2):181-2. PubMed ID: 18083009
    [No Abstract]   [Full Text] [Related]  

  • 25. A promising drug delivery candidate (CS-g-PMDA-CYS-fused gold nanoparticles) for inhibition of multidrug-resistant uropathogenic
    Shi P; Amarnath Praphakar R; Deepa S; Suganya K; Gupta P; Ullah R; Bari A; Murugan M; Rajan M
    Drug Deliv; 2020 Dec; 27(1):1271-1282. PubMed ID: 32885688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unusual aminoglycoside susceptibility pattern and mechanisms of resistance of Serratia marcescens strains from Italy.
    Kettner M; Krcméry V; Bonini P; Cichero P; Ossi C; Grazioli V
    Infection; 1991; 19(4):253. PubMed ID: 1917041
    [No Abstract]   [Full Text] [Related]  

  • 27. [Serratia infections].
    Gomi H
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():385-9. PubMed ID: 12722248
    [No Abstract]   [Full Text] [Related]  

  • 28. SME-2-producing Serratia marcescens isolate from Switzerland.
    Poirel L; Wenger A; Bille J; Bernabeu S; Naas T; Nordmann P
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2282-3. PubMed ID: 17420208
    [No Abstract]   [Full Text] [Related]  

  • 29. Outbreak of Serratia marcescens Coproducing ArmA and CTX-M-15 Mediated High Levels of Resistance to Aminoglycoside and Extended-Spectrum Beta-Lactamases, Algeria.
    Batah R; Loucif L; Olaitan AO; Boutefnouchet N; Allag H; Rolain JM
    Microb Drug Resist; 2015 Aug; 21(4):470-6. PubMed ID: 25884511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro synergistic effects of fisetin and norfloxacin against aquatic isolates of Serratia marcescens.
    Dong J; Ruan J; Xu N; Yang Y; Ai X
    FEMS Microbiol Lett; 2016 Jan; 363(1):fnv220. PubMed ID: 26567906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of the plasmid-mediated quinolone resistance determinants in clinical isolates of Serratia marcescens in China.
    Yang HF; Cheng J; Hu LF; Ye Y; Li JB
    J Antibiot (Tokyo); 2012 Oct; 65(10):531-3. PubMed ID: 22854338
    [No Abstract]   [Full Text] [Related]  

  • 32. Serratia marcescens meningitis: epidemiology, prognostic factors and treatment outcomes.
    Wu YM; Hsu PC; Yang CC; Chang HJ; Ye JJ; Huang CT; Lee MH
    J Microbiol Immunol Infect; 2013 Aug; 46(4):259-65. PubMed ID: 22926070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA‑seq analyses of antibiotic resistance mechanisms in Serratia marcescens.
    Li Z; Xu M; Wei H; Wang L; Deng M
    Mol Med Rep; 2019 Jul; 20(1):745-754. PubMed ID: 31180518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for extended-spectrum beta-lactamase-producing Serratia marcescens and Klebsiella pneumoniae acquisition in a neonatal intensive care unit.
    Crivaro V; Bagattini M; Salza MF; Raimondi F; Rossano F; Triassi M; Zarrilli R
    J Hosp Infect; 2007 Oct; 67(2):135-41. PubMed ID: 17884248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and molecular characterization of extended-spectrum beta-lactamase-producing Enterobacter spp., Pantoea agglomerans, and Serratia marcescens isolates from a Bulgarian hospital.
    Markovska RD; Stoeva TJ; Bojkova KD; Mitov IG
    Microb Drug Resist; 2014 Apr; 20(2):131-7. PubMed ID: 24171449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant Serratia marcescens Isolates from an Outbreak in a Brazilian Teaching Hospital.
    Silva KE; Cayô R; Carvalhaes CG; Patussi Correia Sacchi F; Rodrigues-Costa F; Ramos da Silva AC; Croda J; Gales AC; Simionatto S
    J Clin Microbiol; 2015 Jul; 53(7):2324-8. PubMed ID: 25878341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent emergence of Serratia marcescens in dermatology: retrospective observations based on clinical outpatient data.
    Roh WS; Chung KB; Kim DY
    Eur J Dermatol; 2022 Feb; 32(1):94-98. PubMed ID: 35514104
    [No Abstract]   [Full Text] [Related]  

  • 38. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases.
    Queenan AM; Shang W; Schreckenberger P; Lolans K; Bush K; Quinn J
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3485-7. PubMed ID: 17005839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Carbapenem Resistance in Clinical Gram-Negative Pathogens Isolated in Egypt.
    Khalifa HO; Soliman AM; Ahmed AM; Shimamoto T; Hara T; Ikeda M; Kuroo Y; Kayama S; Sugai M; Shimamoto T
    Microb Drug Resist; 2017 Oct; 23(7):838-844. PubMed ID: 28191865
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.